Managing patients with multivessel coronary artery disease remains a major challenge for cardiologists. Traditionally, clinicians prescribe twelve months of dual antiplatelet therapy after drug-eluting stent implantation. However, whether extending this regimen benefits stable patients remains highly controversial. Recently, a major clinical trial investigated if extended dual antiplatelet therapy reduces long-term ischemic risk in patients with multivessel disease.
The DAPT-MVD Study Design
Therefore, researchers conducted the DAPT-MVD trial at ninety-seven centers in China to evaluate this approach. Specifically, the study enrolled patients aged eighteen to seventy-five with multivessel coronary artery disease. Moreover, these patients had completed twelve months of DAPT without any major ischemic or bleeding events. Consequently, the investigators randomized eighty-two hundred and fifty eligible patients into two equal groups. The first group received extended dual antiplatelet therapy with aspirin and clopidogrel for another year. Meanwhile, the second group received aspirin monotherapy. The primary efficacy outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or stroke. Conversely, the primary safety outcome was clinically relevant or major bleeding.
Key Findings of Extended Dual Antiplatelet Therapy
Significantly, during a median follow-up of thirty-four months, the trial revealed major benefits. For instance, the primary efficacy endpoint occurred in 222 patients in the extended DAPT group. In contrast, 266 patients in the aspirin monotherapy group experienced these ischemic events. Thus, extended therapy reduced the 36-month cumulative incidence of major adverse cardiovascular events from 6.8% to 5.8%. Furthermore, the hazard ratio of 0.82 demonstrated a clear relative risk reduction. Importantly, this benefit did not come at the cost of safety. Clinically relevant or major bleeding rates were virtually identical between the groups. Specifically, bleeding occurred in 51 patients on extended therapy versus 57 patients on aspirin alone. Therefore, the treatment demonstrated high safety.
Clinical Implications for Multivessel CAD Patients
These results provide crucial evidence for tailoring post-PCI antiplatelet strategies. Traditionally, cardiologists often worry about the bleeding penalty of prolonged therapy in clinical practice. However, this study shows that extended treatment offers protection without increasing bleeding risks. Specifically, this safety profile likely stems from enrolling patients who tolerated the initial therapy without complications. Consequently, clinicians should consider extending DAPT with clopidogrel and aspirin for stable multivessel CAD patients. Such customized strategies can significantly prevent recurrent heart attacks and strokes. Nevertheless, physicians must still evaluate individual patient bleeding risks before making decisions. Ultimately, this landmark trial supports a personalized approach to maximize ischemic protection.
Frequently Asked Questions
Q1: What did the DAPT-MVD trial demonstrate about extended dual antiplatelet therapy?
Significantly, the trial demonstrated that extending dual antiplatelet therapy reduces ischemic events. Specifically, it lowered cardiovascular death, myocardial infarction, or stroke without increasing bleeding risks.
Q2: Who was eligible for extended dual antiplatelet therapy in this trial?
Eligible patients were aged eighteen to seventy-five with multivessel CAD. Furthermore, they had successfully completed twelve months of therapy without any ischemic or bleeding events.
Q3: Did extended therapy increase the risk of bleeding compared to aspirin monotherapy?
No, the trial showed very low bleeding rates. Consequently, bleeding risks were virtually identical between the two groups.
References
- Tian J et al. Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. N Engl J Med. 2026 Jul 16. doi: 10.1056/NEJMoa2517588. PMID: 42456136.
- Ruan Z et al. Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial. Clin Cardiol. 2024 Dec;47(12):e70049. doi: 10.1002/clc.70049. PMID: 39587825.